|
WO2020214083A1
|
|
Therapeutic microvesicles of probiotic bacteria
|
|
WO2020020984A1
|
|
Therapeutic methods using bacterial strains which are capable of increasing adenosine levels
|
|
CN112236513A
|
|
Selection and use of melatonin-supporting bacteria to reduce infant colic
|
|
GB201905591D0
|
|
Therapeutic method
|
|
GB201905592D0
|
|
Therapeutic method
|
|
GB201905470D0
|
|
Selection method
|
|
GB201812079D0
|
|
Selection method
|
|
CN110462022A
|
|
Lactic acid bacteria, its method and purposes
|
|
WO2018083336A1
|
|
Activated lactobacillus reuteri strains for selective pathogen inhibition in a human microbial community
|
|
US2019134115A1
|
|
Activated Lactobacillus Reuteri Strains for Selective Pathogen Inhibition in a Human Microbial Community
|
|
EP3463385A1
|
|
Use of inosine for the treatment of t-reg deficiency
|
|
MX2018013660A
|
|
Selection of bacterial strains useful in allergy treatment.
|
|
WO2017060491A1
|
|
Mucus thickness to prevent diseases
|
|
KR20170128245A
|
|
Histamine-producing bacterial strains and their use in cancer
|
|
WO2016113365A1
|
|
Lactic acid bacteria and their use for the treatment of mastitis
|
|
RU2723687C2
|
|
Using lactobacillus reuteri for recovering microbiota after dysbiosis at early stages of development
|
|
GB201517912D0
|
|
Mucus thickness
|
|
US2017095516A1
|
|
In ovo delivery of probiotic cultures
|
|
CN106879253A
|
|
Neonate's microorganism group is supplemented
|
|
WO2015112083A1
|
|
Selection of agents modulating gastrointestinal pain
|
